These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6160811)

  • 41. 9-beta-D-arabinofuranosyl-adenine 5' monophosphate coupled to lactosaminated albumin is not metabolized in mouse bloodstream.
    Fiume L; Balboni PG; Bassi B; Busi C; Mattioli A; Spinosa G
    Pharm Acta Helv; 1986; 61(12):342-4. PubMed ID: 2433700
    [No Abstract]   [Full Text] [Related]  

  • 42. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.
    Richards DM; Carmine AA; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Nov; 26(5):378-438. PubMed ID: 6315332
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic approaches to varicella-zoster virus infections.
    Whitley RJ
    J Infect Dis; 1992 Aug; 166 Suppl 1():S51-7. PubMed ID: 1378081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation of cytotoxicity with total intracellular exposure to 9-beta-D-arabinofuranosyladenine 5'-triphosphate.
    Shewach DS; Plunkett W
    Cancer Res; 1982 Sep; 42(9):3637-41. PubMed ID: 6179604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential inhibition of mammalian DNA polymerases alpha, beta and gamma and herpes simplex virus-induced DNA polymerase by the 5'-triphosphates of arabinosyladenine and arabinosylcytosine.
    Reinke CM; Drach JC; Shipman C; Weissbach A
    IARC Sci Publ (1971); 1978; (24 Pt 2):999-1005. PubMed ID: 87370
    [No Abstract]   [Full Text] [Related]  

  • 46. Anti-herpes activity of adenine arabinoside monophosphate.
    Trobe JD; Centifanto Y; Zam ZS; Varnell E; Kaufman HE
    Invest Ophthalmol; 1976 Mar; 15(3):196-9. PubMed ID: 1254407
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Iontophoretic application of adenine arabinoside monophosphate to herpes simplex virus type 1-infected hairless mouse skin.
    Park NH; Gangarosa LP; Kwon BS; Hill JM
    Antimicrob Agents Chemother; 1978 Oct; 14(4):605-8. PubMed ID: 82423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the efficacy of vidarabine, its carbocyclic analog (cyclaradine), and cyclaradine-5'-methoxyacetate in the treatment of herpes simplex virus type 1 encephalitis in mice.
    Shannon WM; Westbrook L; Arnett G; Daluge S; Lee H; Vince R
    Antimicrob Agents Chemother; 1983 Oct; 24(4):538-43. PubMed ID: 6651280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Arabinosyladenine monophosphate in genital herpes: a double-blind, placebo-controlled study.
    Hatcher VA; Friedman-Kien AE; Marcus EL; Klein RJ
    Antiviral Res; 1982 Oct; 2(5):283-90. PubMed ID: 6185089
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vidarabin-monophosphate, BCNU, VM26--an in vitro comparative study of active agents in the treatment of malignant human brain tumours.
    Bogdahn U; Zapf J; Weber H; Dünisch G; Löbering HG; Martin R; Mertens HG
    Br J Cancer; 1987 Feb; 55(2):153-8. PubMed ID: 2434122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiviral treatment in chickenpox and herpes zoster.
    Huff JC
    J Am Acad Dermatol; 1988 Jan; 18(1 Pt 2):204-6. PubMed ID: 3339143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-herpesvirus activity of adenine arabinoside analogues in tissue culture and a genital infection of mice and guinea pigs.
    Richards JT; Kern ER; Overall JC; Glasgow LA
    Antiviral Res; 1982 May; 2(1-2):27-39. PubMed ID: 6179469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-performance liquid chromatographic analysis of hypoxanthine arabinoside in plasma.
    Smith GA; Giacomini KM; Smith CT; Gregory PB; Robinson WS; Merigan TC; Blaschke TF
    J Chromatogr; 1984 May; 307(2):410-5. PubMed ID: 6203924
    [No Abstract]   [Full Text] [Related]  

  • 54. Antiviral activity in the rabbit cornea of adenine arabinoside, Ara-A 5' monophosphate, and hypoxanthine arabinoside; and interactions with adenosine deaminase inhibitor.
    Falcon MG; Jones BR
    J Gen Virol; 1977 Jul; 36(1):199-202. PubMed ID: 196039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of factors influencing response rate to antiviral therapy of chronic hepatitis B virus infection. A review of the efficacy of adenine arabinoside and lymphoblastoid interferon in the Royal Free Hospital studies.
    Scully LJ; Lever AM; Yap I; Pignatelli M; Thomas HC
    J Hepatol; 1986; 3 Suppl 2():S291-9. PubMed ID: 2439575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis.
    Hoofnagle JH; Hanson RG; Minuk GY; Pappas SC; Schafer DF; Dusheiko GM; Straus SE; Popper H; Jones EA
    Gastroenterology; 1984 Jan; 86(1):150-7. PubMed ID: 6196251
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use.
    Whitley R; Alford C; Hess F; Buchanan R
    Drugs; 1980 Oct; 20(4):267-82. PubMed ID: 6998693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The virostatic effect of adenine-arabinoside monophosphate. Experimental findings and preliminary clinical experiences].
    Werner GT; Bömer H; Metzger E; Sauer O; Schneider H; Schubert E; Treuner J
    Fortschr Med; 1978 Aug; 96(32):1589-97. PubMed ID: 680620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure.
    Aronoff GR; Szwed JJ; Nelson RL; Marcus EL; Kleit SA
    Antimicrob Agents Chemother; 1980 Jul; 18(1):212-4. PubMed ID: 7416747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Iontophoresis of vidarabine monophosphate for herpes orolabialis.
    Gangarosa LP; Hill JM; Thompson BL; Leggett C; Rissing JP
    J Infect Dis; 1986 Dec; 154(6):930-4. PubMed ID: 2431074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.